VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+0.85%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$20.5M
(-9.7%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-6.22%
Top 10 Holdings %
Top 10 Hldgs %
8%
Holding
450
New
8
Increased
100
Reduced
215
Closed
125
Top Buys
| 1 |
Brookfield Infrastructure
BIPC
|
$1.15M |
| 2 |
ECC
Eagle Point Credit Co
ECC
|
$1.05M |
| 3 |
OXLC
Oxford Lane Capital
OXLC
|
$1.03M |
| 4 |
ORAN
Orange
ORAN
|
$395K |
| 5 |
SNP
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
|
$391K |
Top Sells
| 1 |
Delek Logistics
DKL
|
$2.05M |
| 2 |
Western Midstream Partners
WES
|
$788K |
| 3 |
CNXM
CNX Midstream Partners LP
CNXM
|
$744K |
| 4 |
OSB
Norbord Inc.
OSB
|
$657K |
| 5 |
Lamar Advertising Co
LAMR
|
$515K |
Sector Composition
| 1 | Healthcare | 32.34% |
| 2 | Real Estate | 18.02% |
| 3 | Energy | 12.43% |
| 4 | Materials | 10.7% |
| 5 | Financials | 6.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Novavax
NVAX
$1.19B
| $733K | 0.38% |
6,766
-926
| -12% | -$100K |
|
|
PSXP
102
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $732K | 0.38% |
31,770
+3,956
| +14% | +$91.1K |
|
103
Ultragenyx Pharmaceutical
RARE
$3.04B
| $706K | 0.37% |
8,587
+723
| +9% | +$59.4K |
|
104
Travere Therapeutics
TVTX
$1.75B
| $704K | 0.37% |
38,150
+3,213
| +9% | +$59.3K |
|
105
CVR Energy
CVI
$3.1B
| $695K | 0.36% |
56,147
+6,604
| +13% | +$81.7K |
|
106
Insmed
INSM
$30.5B
| $691K | 0.36% |
21,496
+1,811
| +9% | +$58.2K |
|
107
MidCap Financial Investment
MFIC
$1.21B
| $690K | 0.36% |
83,492
-10,355
| -11% | -$85.6K |
|
|
XLRN
108
DELISTED
Acceleron Pharma Inc.
XLRN
| $690K | 0.36% |
6,129
+516
| +9% | +$58.1K |
|
109
Amgen
AMGN
$153B
| $682K | 0.36% |
2,683
+227
| +9% | +$57.7K |
|
110
Alnylam Pharmaceuticals
ALNY
$59.6B
| $679K | 0.36% |
4,662
+393
| +9% | +$57.2K |
|
111
Halozyme
HALO
$8.81B
| $673K | 0.35% |
25,612
+2,157
| +9% | +$56.7K |
|
112
Exelixis
EXEL
$10.1B
| $638K | 0.33% |
26,104
+2,199
| +9% | +$53.7K |
|
|
ALXN
113
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $612K | 0.32% |
5,347
+181
| +4% | +$20.7K |
|
114
Biogen
BIIB
$20.5B
| $594K | 0.31% |
2,093
+121
| +6% | +$34.3K |
|
115
Vertex Pharmaceuticals
VRTX
$102B
| $592K | 0.31% |
2,176
-3
| -0.1% | -$816 |
|
116
Kura Oncology
KURA
$709M
| $579K | 0.3% |
18,907
-2,572
| -12% | -$78.8K |
|
117
Ironwood Pharmaceuticals
IRWD
$185M
| $575K | 0.3% |
63,946
+5,386
| +9% | +$48.4K |
|
118
Barings BDC
BBDC
$981M
| $572K | 0.3% |
71,531
-60,976
| -46% | -$488K |
|
119
Incyte
INCY
$17.1B
| $570K | 0.3% |
6,348
+535
| +9% | +$48K |
|
120
BlackRock TCP Capital
TCPC
$608M
| $564K | 0.3% |
57,530
-14,277
| -20% | -$140K |
|
121
Regeneron Pharmaceuticals
REGN
$60.4B
| $556K | 0.29% |
994
+13
| +1% | +$7.27K |
|
122
PTC Therapeutics
PTCT
$4.43B
| $555K | 0.29% |
11,863
+999
| +9% | +$46.7K |
|
123
Enanta Pharmaceuticals
ENTA
$192M
| $551K | 0.29% |
12,046
+1,015
| +9% | +$46.4K |
|
124
Prospect Capital
PSEC
$1.33B
| $531K | 0.28% |
105,608
-29,786
| -22% | -$150K |
|
125
PennantPark Floating Rate Capital
PFLT
$1.02B
| $530K | 0.28% |
62,760
-13,385
| -18% | -$113K |
|